Edition:
United Kingdom

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,625.00GBp
20 Jul 2017
Change (% chg)

14.50 (+0.90%)
Prev Close
1,610.50
Open
1,611.00
Day's High
1,630.00
Day's Low
1,609.50
Volume
7,359,688
Avg. Vol
9,349,315
52-wk High
1,745.56
52-wk Low
1,446.50

GSK.L

Chart for GSK.L

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 1.19
Market Cap(Mil.): £79,211.13
Shares Outstanding(Mil.): 4,918.42
Dividend: 19.00
Yield (%): --

Financials

  GSK.L Industry Sector
P/E (TTM): 47.11 13.49 17.10
EPS (TTM): 0.34 -- --
ROI: 5.27 -7.23 -5.56
ROE: 74.13 -6.74 -4.84

BRIEF-GSK to sell UK Horlicks business

* Proposals announced today for Worthing and Slough will result in a reduction of approximately 320 permanent jobs over next 4 years

19 Jul 2017

BRIEF-GSK begins shipping quadrivalent vaccine doses to U.S. healthcare providers

* Glaxosmithkline Plc says begun shipping quadrivalent vaccine doses to U.S. healthcare providers

14 Jul 2017

BRIEF-Oncomed says GSK terminates license agreement with company

* Oncomed Pharmaceuticals Inc - on July 7, received a letter, dated June 30, 2017 from Glaxosmithkline LLC- SEC filing

10 Jul 2017

BRIEF-Egypt's Glaxosmithkline Q1 standalone loss narrows

* Q1 standalone net loss after tax EGP 45.6 million versus loss of EGP 69 million year ago

06 Jul 2017

BRIEF-Glaxosmithkline starts phase III study for nasal polyps drug

* GSK starts phase III study with Mepolizumab in patients with nasal polyps

27 Jun 2017

BRIEF-GSK CEO Walmsley pursuing sale of Maxinutrition brand - Sky News

* Glaxosmithkline Plc CEO Emma Walmsley is pursuing a sale of Maxinutrition, a nutritional products brand - Sky News Source text : http://bit.ly/2s0Hw4u Further company coverage:

22 Jun 2017

GSK wins $235 million from Teva in Coreg patent trial

A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million (£185 million) for infringing a patent covering its blood pressure drug Coreg, court documents showed.

21 Jun 2017

GSK wins $235 million from Teva in Coreg patent trial

A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents showed.

21 Jun 2017

GSK wins $235 million from Teva in Coreg patent trial

June 21 A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents showed.

21 Jun 2017

BRIEF-GlaxoSmithKline announces positive results from two phase III studies of Tafenoquine​

* ‍GSK and Medicines for Malaria Venture announced positive results from two phase III studies of Tafenoquine​

12 Jun 2017

Earnings vs. Estimates